I-Mab Biopharma

Contributing Author

Recent Articles by I-Mab Biopharma

Aug-01	I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares IMAB +30.35% GlobeNewswire
Jul-17	I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health IMAB GlobeNewswire
Jul-14	I-Mab to Present at the BTIG Virtual Biotechnology Conference IMAB GlobeNewswire
Jul-02	I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 IMAB GlobeNewswire
Jun-30	I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research IMAB GlobeNewswire
Jun-26	I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 IMAB GlobeNewswire
Jun-18	I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025 IMAB GlobeNewswire
Jun-12	I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement IMAB GlobeNewswire
Jun-03	I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series IMAB GlobeNewswire
May-20	I-Mab to Present at Jefferies Global Healthcare Conference IMAB GlobeNewswire
May-15	I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update IMAB GlobeNewswire